Navigation Links
MedImmune Submits Biologics License Application to FDA for Motavizumab
Date:2/4/2008

GAITHERSBURG, Md., Feb. 4 /PRNewswire/ -- MedImmune announced today it submitted to the U.S. Food & Drug Administration (FDA) on January 30 a Biologics License Application (BLA) for motavizumab, an investigational monoclonal antibody (MAb) derived from recombinant DNA technology. The motavizumab BLA is supported by clinical trial data from more than 6,000 patients in which safety and efficacy in prevention of serious disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients were evaluated.

"We are pleased to submit this BLA for motavizumab, which we believe represents another tool in the fight against RSV. This marks a significant milestone for this molecule and further reinforces MedImmune's commitment to developing anti-RSV biologics for the underserved pediatric patient population," said Linda J. Peters, senior vice president, regulatory affairs.

Motavizumab was studied in an active-controlled Phase 3 trial against the standard of care in pediatric patients at high risk of serious RSV disease. Primary and secondary endpoints of the study included incidence of RSV hospitalizations and RSV-specific medically attended outpatient lower respiratory tract infections. Rates of adverse events, serious adverse events and study drug discontinuations were balanced between treatment groups. The most frequently observed reactions versus the active comparator were cutaneous reactions (overall).

"Beyond the findings of the various investigational trials for motavizumab, we believe this molecule will help reinforce the positive role that MAbs play in RSV prevention within the current clinical body of evidence. It also reinforces our position as a leader in RSV prevention," said Genevieve Losonsky, M.D., vice president, clinical development, infectious disease.

RSV is a leading cause of viral respiratory infection among infants. Each year, up to an estimated 125,000 infants in the United States are hospitalized with sev
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
2. MedImmune Announces Seven Key Promotions and New Hires
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
6. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
7. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Cephalon Submits Supplemental New Drug Application for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... worldwide rely on sophisticated equipment, trained personnel, and ... areas against terrorist attacks. A revolutionary new electronic ... make their job much easier. , The groundbreaking ... Tel Aviv University ,s School of Chemistry and ... the Herzliya company Tracense, picks up the scent ...
(Date:7/24/2014)... processes prefer to settle into equilibriuma state of ... the realm of non-equilibrium conditions where new possibilities ... and phases, such as temperature fluctuations, freezing and ... regulate their body temperature, airplanes to fly, and ... , But even though these conditions exist naturally ...
(Date:7/24/2014)... , July 24, 2014 SRI International ... with the National Institute of Allergy and Infectious Diseases ... conduct preclinical development of potential therapies for HIV infection ... to treat HIV and AIDS and the complications and ... microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... LANSING, Mich. , July 24, 2014  Neogen ... today that future forecasts of its potential revenue from ... conference call to investors and analysts on July 22, ... questioned by analysts regarding this research. "It ... answer questions about the potential of a new type ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Neogen comments on SenesTech 2
... SectorWatch.biz announces the,availability of MarketStats on public equities ... Investors can view all of SectorWatch.biz MarketStats ... Click on MarketStats, Today,s MarketStats on Healthcare ... Bulletin Board: CVBT), Boston,Scientific Corp. (NYSE: BSX ...
... DIEGO, Feb. 14 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... and,year-end 2007 financial results on Wednesday, February 20, 2008, ... a conference call and webcast to discuss its fourth,quarter ... its,development programs on Wednesday, February 20, 2008 at 5:00 ...
... Feb. 14 AspenBio Pharma,Inc. (Nasdaq: APPY ) ... drugs and diagnostics for animals and humans, has been,invited ... Growth Stock,Conference. The conference will be held February 18-21, ... California., Roth Capital Partners Stock Conferences are one ...
Cached Biology Technology:SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA 2Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results 2AspenBio Pharma to Present at the Roth Capital Partners 20th Annual Growth Stock Conference 2
(Date:7/27/2014)... at Barts Cancer Institute have found that targeting a ... more effective, according to research published in Nature ... part of Queen Mary University of London, have found ... the body to repair itself after chemotherapy or radiotherapy, ... researchers removed FAK from blood vessels that grew in ...
(Date:7/25/2014)... 100,000s of people lived on the land now called ... control the availability of plants they used for food, ... fire to maintain desired habitat and natural resources. , ... Pacific Southwest Station, will lead a field trip ... the Ecological Society of America,s 99th Annual Meeting, in ...
(Date:7/25/2014)... study published online in the International Journal of ... to preventing cervical cancer based on findings showing successful ... of a discrete population of cells in the cervix. ... looked at squamocolumnar junction cells, or SCJ cells. These ... implicated as the origins of cervical cancer. A research ...
Breaking Biology News(10 mins):New drug target can break down cancer's barrier against treatment 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3Clearing cells to prevent cervical cancer 2
... The New York Genome Center (NYGC) announced today ... become an Associate Member, joining NYGC,s growing consortium of ... new ways to utilize genomic data for better detection, ... NYSCF working with the genomic scientists at NYGC will ...
... an excellent economics teacher, but some would be surprised to ... is cleaner than the first breath they ever took. ... that improvements in U.S. air quality since 1990 have sparked ... to air pollution. Pope was a member of a large ...
... of popular soft drinks, alters the brain,s perception of ... determine the difference between sugar and artificial sweeteners, according ... official journal of the American Gastroenterological Association. ... and artificial sweeteners can leave the sweet taste of ...
Cached Biology News:New York Genome Center announces the New York Stem Cell Foundation as an Associate Member 2New York Genome Center announces the New York Stem Cell Foundation as an Associate Member 3Death & disability from air pollution down 35 percent in the US 2Carbonation alters the mind's perception of sweetness 2
... FX provides complete solutions for ... With 96-, 384-, and independent ... either single or dual arm ... maximum speed and flexibility for ...
... fixed-angle microcentrifuge rotor at RCF up ... filters consist of a membrane-containing filter ... filter by centrifugation for bacteria removal, ... of cells from media and DNA ...
... System provides high-throughput, quantitative gene expression analysis ... patented priming strategy overcomes the biases that ... a few genes at a time. ... and more samples per run, removing bottlenecks ...
... Detergent-OUT Kit is a simple high performance ... Removes detergents without significant dilution of ... solution on the Detergent-OUT Spin column and ... Med column is suitable for removing detergents ...
Biology Products: